On Nov. 26, 2025, Medicare announced lower prices for 15 drugs after a second round of negotiations with pharmaceutical companies. The list includes Ozempic (diabetes/weight loss), asthma medications, breast cancer drugs, and leukemia treatments. The negotiations are part of the Inflation Reduction Act's drug pricing provisions allowing Medicare to directly negotiate prices with manufacturers. First-round negotiations in 2024 covered 10 drugs. The pharmaceutical industry opposed these negotiations, arguing they stifle innovation, while patient advocates say they reduce costs for seniors and Medicare.

No core facts available for this topic.